FORMULARY WATCH

Opioid overdose

FDA grants naloxone spray priority review

By Tracey Walker
FDA has granted priority review to naloxone nasal spray (Indivior) for the treatment of opioid overdose. If approved, naloxone nasal spray is expected to be the first FDA-approved intranasal naloxone product indicated to treat opioid overdose in the United States. 3 naloxone facts

CONTINUING EDUCATION

MTM essentials for COPD Management: Part 2

This month's CE activity is part of the CPE series, "Medication Therapy Management for the Patient with Respiratory Disease." From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to assist pharmacists in understanding strategies for improving patient outcomes related to COPD management.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT32-KZV23.

The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php.
To review you registration page to ensure the data is up to date, or to register, go
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

The first PCSK9 inhibitor approval: 5 lessons

By Tracey Walker
With FDA’s approval of Praluent (alirocumab) injection, the first in a new class of injectable cholesterol-lowering drugs called PCSK9 inhibitors, comes 5 important lessons. Read more

August 3, 2015